Physician profile
Daniela M Tabacaru
NPI 1730384181
$2,326.49
in general payments reported to CMS, 2019-2025
9 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $18.22 · 2022: $124 · 2023: $485 · 2024: $447 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $922.80 | 2023-2025 | Auvelity |
| Neuronetics, INC. | $701.33 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $234.25 | 2019-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $124.55 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $124.08 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.30 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $42.99 | 2019 | |
| Allergan, INC. | $34.73 | 2019-2020 | |
| Lundbeck LLC | $20.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Tabacaru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.